Back to results
US 11,891,664 B2Granted
Methods of detecting renal transplant rejection using microvesicle nucleic acid biomarkers
AssigneesExosome Diagnostics, Inc., The Brigham and Women's Hospital, Inc.
InventorsJames Hurley, Christine Coticchia, Robert Kitchen, Vasisht Tadigotla, Johan Karl Olov Skog, Jamil Azzi
Life of this patent
Estimating the term…
Abstract
The invention relates generally to the use of microvesicle biomarkers such as nucleic acids, including nucleic acid signatures, and/or proteins for assessing a kidney transplant rejection in a patient. The invention further relates to assessing, and/or to monitoring kidney transplant rejection in patients who have received a renal transplant.
Claims8
A method of treating a kidney transplant rejection in a patient, the method comprising the steps of:
- a) isolating a microvesicle fraction from a urine sample from the patient;
- b) extracting nucleic acids from the microvesicle fraction;
- c) determining the expression levels of at least two biomarkers from the extracted nucleic acids, wherein the at least two biomarkers comprise each of CXCL9 and CXCL10, and the expression level of at least one normalizing gene, wherein the at least one normalizing gene comprises IL17RA;
- d) normalizing the expression levels of the at least two biomarkers to the expression level of the at least one normalizing gene;
- e) determining that the patient is undergoing a kidney transplant rejection based on the normalized expression levels of the at least two biomarkers;
- and
- f) administering at least one kidney transplant rejection therapy to the patient undergoing a kidney transplant rejection.
4 more elements
Dependencies are inferred from the claim text.